Literature DB >> 7516271

Some patients with anti-myeloperoxidase autoantibodies have a C-ANCA pattern.

M Segelmark1, B Baslund, J Wieslander.   

Abstract

Rapidly progressive glomerulonephritis with or without other signs of systemic vasculitis is often accompanied by antibodies to myeloperoxidase. Such antibodies normally produce a perinuclear pattern on ethanol-fixed neutrophils (perinuclear anti-neutrophil cytoplasm antibodies (P-ANCA)) at indirect immunofluorescence. We report here sera from three patients that are anti-myeloperoxidase-positive in ELISA that instead produce a cytoplasmic pattern (classical anti-neutrophil cytoplasmic antibodies (C-ANCA)), a pattern normally seen in conjunction with antibodies to proteinase 3. These sera did not react with proteinase 3. For two of the sera the specificity of the anti-myeloperoxidase reaction was confirmed with inhibition-ELISA experiments and with immunoblotting. A mouse anti-myeloperoxidase MoAb that produces a cytoplasmic pattern is also described. Competition ELISA experiments show that this antibody and anti-myeloperoxidase sera with cytoplasmic pattern recognize epitopes that are separate from epitopes recognized by another perinuclear pattern producing anti-myeloperoxidase MoAb. 'Cytoplasmic pattern' epitopes as well as 'perinuclear pattern' epitopes can be found on all three major myeloperoxidase isoforms, after separation by ion exchange chromatography. Affinity chromatography, using the cytoplasmic pattern producing anti-myeloperoxidase monoclonal antibody, shows that the epitope recognized by this MoAb is present on all myeloperoxidase molecules. This epitope is not confined to any special subpopulation. These findings indicate that all myeloperoxidase do not relocate after ethanol fixation, and that C-ANCA and P-ANCA epitopes exist simultaneously on the same myeloperoxidase molecule. We propose that the two immunofluorescence patterns arise due to different availabilities of the epitopes in the microenvironment where myeloperoxidase is present.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516271      PMCID: PMC1534554          DOI: 10.1111/j.1365-2249.1994.tb06051.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

Review 1.  ANCA-associated renal disease.

Authors:  R J Falk
Journal:  Kidney Int       Date:  1990-11       Impact factor: 10.612

2.  Delineation of a standard procedure for indirect immunofluorescence detection of ANCA.

Authors:  A Wiik
Journal:  APMIS Suppl       Date:  1989

3.  Wegener's granulomatosis with antiproteinase-3 antibodies occurring after Hodgkin's disease.

Authors:  P Gratadour; D Fouque; M Laville; J Fourcade; M Ffrench; S Colon; F Berger; R Loire; J F Cordier; P Zech
Journal:  Nephron       Date:  1993       Impact factor: 2.847

4.  Characterization of monoclonal antibodies to the globular domain of collagen IV.

Authors:  C Johansson; R Butkowski; J Wieslander
Journal:  Connect Tissue Res       Date:  1991       Impact factor: 3.417

5.  Distinct chromatographic forms of human hemi-myeloperoxidase obtained by reductive cleavage of the dimeric enzyme. Evidence for subunit heterogeneity.

Authors:  K L Taylor; G S Guzman; J Pohl; J M Kinkade
Journal:  J Biol Chem       Date:  1990-09-15       Impact factor: 5.157

6.  Reactivity of anti-neutrophil cytoplasmic autoantibodies with HL-60 cells.

Authors:  L A Charles; R J Falk; J C Jennette
Journal:  Clin Immunol Immunopathol       Date:  1989-11

7.  Unique autolytic cleavage of human myeloperoxidase. Implications for the involvement of active site MET409.

Authors:  K L Taylor; J Pohl; J M Kinkade
Journal:  J Biol Chem       Date:  1992-12-15       Impact factor: 5.157

8.  Anti-myeloperoxidase autoantibodies react with native but not denatured myeloperoxidase.

Authors:  R J Falk; M Becker; R Terrell; J C Jennette
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

Review 9.  ANCA and associated diseases: immunodiagnostic and pathogenetic aspects.

Authors:  W L Gross; W H Schmitt; E Csernok
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

10.  Anti-neutrophil cytoplasm antibodies in patients with monoclonal gammopathies.

Authors:  V L Esnault; D R Jayne; M T Keogan; A A Brownlee; A Testa; D Lecarrer; D L Brown; C M Lockwood
Journal:  J Clin Lab Immunol       Date:  1990-08
View more
  17 in total

1.  Immunofluorescent patterns produced by antineutrophil cytoplasmic antibodies (ANCA) vary depending on neutrophil substrate and conjugate.

Authors:  W Pollock; K Clarke; K Gallagher; J Hall; E Luckhurst; R McEvoy; J Melny; J Neil; A Nikoloutsopoulos; T Thompson; M Trevisin; J Savige
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

Review 2.  ANCA testing. New developments and clinical implications.

Authors:  A E Ahmed; J B Peter; Y Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 3.  The clinical utility of ANCA positivity.

Authors:  J D Edgar
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

4.  A challenging diagnosis of MPO-C-ANCA EGPA.

Authors:  Gareth Lim; Sheryl Lim; Shang-Ian Tee; Chai Yiing Ling
Journal:  BMJ Case Rep       Date:  2019-07-10

5.  IgM anti-myeloperoxidase antibody-secreting lymphocytes are present in the peripheral repertoire of lupus mice but rarely differentiate into IgG-producing cells.

Authors:  O Vittecoq; F Brard; F Jovelin; X Le Loet; F Tron; D Gilbert
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

6.  Anticytokeratins are a potential source of false-positive indirect immunofluorescence assays for C-ANCA.

Authors:  J Streicher; B Fabian; K Herkner; H Pointner; P M Bayer
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

7.  Increased monocyte transcription of the proteinase 3 gene in small vessel vasculitis.

Authors:  S Ohlsson; T Hellmark; K Pieters; G Sturfelt; J Wieslander; M Segelmark
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

8.  A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies.

Authors:  J A Savige; B Paspaliaris; R Silvestrini; D Davies; T Nikoloutsopoulos; A Sturgess; J Neil; W Pollock; K Dunster; M Hendle
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

9.  Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis.

Authors:  Mårten Segelmark; Brian D Phillips; Susan L Hogan; Ronald J Falk; J Charles Jennette
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

Review 10.  Antineutrophil cytoplasmic autoantibodies: how should the biologist manage them?

Authors:  C Beauvillain; Y Delneste; G Renier; P Jeannin; J F Subra; A Chevailler
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.